

# June 5, 2024 Wednesday

10:00	Registration – Hotel Lobby
12:00-13:00	Lunch - Mátra Restaurant
13:00-13:45	<b>Opening of the Conference</b> <b>Issekutz Presentation and Award Ceremony</b> <b>Knoll-Szolcsányi Award Ceremony</b> <b>Award ceremony of the Young Pharmacologist Researcher competition</b>
13:45-14:15 W-K1	<b>KEYNOTE 1 - András Perczel - Sponsored by Auro-Science Consulting Ltd.</b> Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary <i>A drug-drug interaction (valproate and a carbapenem) explained by the first cryo-EM determined 3D structures of the mammalian acylaminoacyl peptidase</i>
14:15-15:45 W-K2	<b>Epigenetics and human disease</b> <u>Chair:</u> Gábor Szabó W-K2-1 <sup>1</sup> Viktória Tisza, <sup>2</sup> Laura Vízkeleti, <sup>1</sup> Csaba Kiss, <sup>1</sup> <b>Sándor Spisák 15'+3'</b> <sup>1</sup> HUN-REN TTK, Institute of Molecular Life Science, Epigenetics and Genome Editing Research Group, Budapest, Hungary <sup>2</sup> Semmelweis University, Department of Bioinformatics, Budapest, Hungary <i>Identification of Epigenetic Mechanisms Influencing Cell Differentiation Block in Colorectal Cancer Development</i> W-K2-2 <sup>1</sup> Dalma Müller, <sup>1,2</sup> Balázs Győrffy <b>15'+3'</b> <sup>1</sup> Semmelweis University, Department of Bioinformatics, Budapest, Hungary <sup>2</sup> TTK Oncology Biomarker Research Group, Budapest, Hungary <i>EpigenPlot: a tool for the gene-level methylation analysis of colorectal tumors</i> W-K2-3 <sup>1</sup> Márton Dániel Tóth, <sup>1</sup> Muhyiddeen Muazu, <sup>2</sup> Dóra Kővári, <sup>2</sup> Andrea Kadar, <sup>3</sup> Tamatey Virgil, <sup>1</sup> Mária Ashaber, <sup>4</sup> Klára Lévay, <sup>5</sup> András Budai, <sup>4</sup> András Fülöp, <sup>2</sup> Csaba Fekete, <sup>3</sup> Flora Szeri, <sup>1,3</sup> <b>Tamás Arányi 15'+3'</b> <sup>1</sup> Department of Molecular Biology, Semmelweis University, Budapest, Hungary <sup>2</sup> Institute of Experimental Medicine, Budapest, Hungary <sup>3</sup> Research Centre for Natural Sciences, Institute of Molecular Life Sciences, HUN_REN, Budapest, Hungary <sup>4</sup> Department of Surgery, Transplantation and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary

<sup>5</sup>2nd Department of Pathology, Semmelweis University, Budapest, Hungary

*Hepatocyte-specific Dnmt3a and DNMT3b mice develop pre-cancerous phenotype*

**W-K2-4** **<sup>1</sup>Gábor Szabó, <sup>1</sup>Péter Nánási, <sup>1</sup>László Imre **15'+3'****

<sup>1</sup>Department of Biophysics and Cell Biology, University of Debrecen

*Nucleosomes: old and new pharmacological targets*

**W-K2-5** **<sup>1</sup>Lóránt Székvölgyi **15'+3'****

<sup>1</sup>Genome Architecture and Recombination Research Group, Faculty of Pharmacy, University of Debrecen

*The role of one-carbon metabolism in R-loop-associated transcriptional changes and mutagenesis*

**15:45-16:15**

**Coffee break**

**16:15-16:30 W-K3** **KEYNOTE 2- Igor Pongrác - Sponsored by Merck Life Science Ltd.**  
**15'**

Merck Life Science | Science and Lab Solutions, Croatia

*Experience the next generation multiplexing with luminex® xmap® intelliflex system and milliplex® multiplex assays*

**16:30-17:15 W-K4**

**PLENARY LECTURE - Sir Mark Caulfield **45'****

Faculty of Medicine and Dentistry, Queen Mary University of London, UK

*Transforming Pharmacogenomics in Healthcare*

**17:15-18:00 W-K5**

**KEYNOTE 3- David A. Kendall **45'****

PharmNovo AB/ Nottingham University, UK

*Development of PN6047, a novel delta opioid receptor agonist for neuropathic pain therapy*

**18:00-18:10**

**Break**

**18:10-20:00 W-K6**

**Young Investigator Session**

Chairs: Éva Szőke, Zoltán Varga

**W-K6-1** **Barbara Takács, Wachal Zita, Szilágyi Anna, Szabó Adrienn Mónika, Priksz Dániel, Bombicz Mariann, Pelles-Taskó Beáta, Juhász Béla, Szilvássy Zoltán, Varga Balázs **10+5'****

Department of Pharmacology and Pharmacotherapy, University of Debrecen, Debrecen

*Key findings from bgp-15 treatment on retinal function improvement in zdf and sprague-dawley rat models*

**W-K6-2** <sup>1,2</sup>**Márton Kocsis**, <sup>1,2</sup>Sayour Viktor Nabil, <sup>1,2</sup>Tóth Viktória, <sup>1,2</sup>Gergely Tamás, <sup>1,2</sup>Kovács Tamás, <sup>1,2</sup>Szabó Lilla, <sup>1,2</sup>Varga Zoltán **10+5'**

<sup>1</sup>Semmelweis University, Budapest

<sup>2</sup>HCEMM, Szeged

*Thymic modulation of immune checkpoint inhibitor-induced cardiotoxicity: new perspectives in immunotherapy*

**W-K6-3** **Angelika Bodó**<sup>1,2,3</sup> Bali ZK<sup>1,3</sup>, Bruszt N<sup>1,2,3,4</sup>, Reisinger Cs<sup>1,3,4</sup>, Hernadi I<sup>1,2,3,4</sup> **10+5'**

<sup>1</sup>Translational Neuroscience Research Group, Grastyán Translational Research Centre, <sup>2</sup>Medical School <sup>3</sup>Szentágothai Research Centre,

<sup>4</sup>Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary

*A pilot study using dreadd technology to develop a novel model of cognitive impairment*

**W-K6-4** <sup>1,2</sup>**Zita Képes**, <sup>1,2</sup>Csaba Csikos, <sup>1</sup>Fekete Anikó, <sup>3</sup>Vágner Adrienn, <sup>3</sup>Nagy Gábor, <sup>1,4</sup>Gyuricza Barbara, <sup>1,5</sup>Arató Viktória, <sup>6</sup>Kárpáti Levente, <sup>7</sup>Mándity István, <sup>8</sup>Bruchertseifer Frank, <sup>9</sup>Halmos Gábor, <sup>1</sup>Szikra Dezső, <sup>1,2</sup>Trencsényi György **10+5'**

University of Debrecen

<sup>1</sup>Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

<sup>2</sup>Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

<sup>3</sup>Scanolmed Ltd., Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

<sup>4</sup>Doctoral School of Chemistry, Faculty of Science and Technology, University of Debrecen, Egyetem square 1, H-4032 Debrecen, Hungary.

<sup>5</sup>Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

<sup>6</sup>Department of Organic Chemistry, Faculty of Pharmacy, Semmelweis University, Hőgyes Endre St. 7, H-1092 Budapest, Hungary.

<sup>7</sup>Artificial Transporters Research Group, Research Centre for Natural Sciences, Magyar tudósok Boulevard 2, H-1117 Budapest, Hungary.

<sup>8</sup>European Commission, Joint Research Centre (JRC), Karlsruhe, Germany.

<sup>9</sup>Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

*Evaluation of the therapeutic efficacy of <sup>213</sup>bi-labelled dota-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model*

**W-K6-5** <sup>1,2</sup>Szonja Anna Kovács, <sup>3</sup>Kovács Tamás, <sup>3</sup>Hegedűs Zsombor, <sup>3</sup>Paál Ágnes, <sup>1,2</sup>Fekete János Tibor, <sup>3</sup>Varga Zoltán, <sup>1,2</sup>Győrffy Balázs **10+5'**

<sup>1</sup>Semmelweis Egyetem, Bioinformatika Tanszék, Budapest

<sup>2</sup>HUN-REN Természettudományi Kutatóközpont, Enzimológiai Intézet, Budapest

<sup>3</sup>Semmelweis Egyetem, Farmakológiai és Farmakoterápiás Intézet, Budapest

*Yap1 inhibitor verteporfin potentiates the effects of anti-pd-1 immunotherapy in melanoma*

**W-K6-6** **Emese Ritter**<sup>1</sup>, Kata Csekő<sup>1,2</sup>, Péter Mátyus<sup>5,6</sup>, Ágnes Kemény<sup>1</sup>, András Garami<sup>7</sup>, Eszter Pákai<sup>7</sup>, Zsuzsanna Helyes<sup>1,2,3,4</sup> **10+5'**

University of Pécs

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School

<sup>2</sup>National Laboratory for Drug Research and Development, Budapest;

<sup>3</sup>HUNREN-PTE Chronic Pain Research Group; <sup>4</sup>PharmInVivo Hungary Ltd, Pécs; <sup>5</sup>Veterinary University, Budapest; <sup>6</sup>E-Group Ltd, Budapest;

<sup>7</sup>Department of Translational Medicine, University of Pécs, Medical School

*The novel multi-target drug candidate szv-1287 inhibits inflammatory lung function alterations in the optimized endotoxin-induced acute pneumonitis mouse model*

**W-K6-7** **Brigitta Bernát**, Vécsei Vencel, Garami Gréta, Bombicz Mariann, Tarjányi Vera, Óvári Ignác, Szilvássy Zoltán, Juhász Béla, Priksz Dániel **10+5'**

Department of Pharmacology and Pharmacotherapy, Debrecen

*Investigation of the cardiac effects of ertugliflozin utilizing high-resolution echocardiography in SHR rat model*

20:00-21:00

Dinner - Mátra Restaurant

# June 6, 2024 Thursday

8:00 Registration- Hotel Lobby

9:00-10:00 T-KA PLENARY LECTURE Thomas Wieland 60'

Medical Faculty, Mannheim Heidelberg University, Germany

*New Avenues to Increase Cardiac Contractility in Heart Failure*

10:00-10:30 Coffee break

10:45-12:30 T-KA1 Fusion Pharmacology: cardio-inflammation in focus

Chairs: Clive Page, Soraia Costa

T-KA1-1 **Gilberto De Nucci 50'**

Faculty of Medical Sciences Unicamp (Campinas-SP, Brazil)

*Pharmacological Actions of Novel Endogenous Catecholamines*

T-KA1-2 **Aisah A Aubdoool,<sup>1</sup> Kristen J Bubb, PhD,<sup>1,2</sup> Amie J Moyes, PhD,<sup>1</sup> Sarah Lewis, MD,<sup>3</sup> Jonathan P Drayton, MD,<sup>1</sup> Owen Tang, PhD,<sup>2</sup> Vedanta Mehta, PhD,<sup>4</sup> Ian C Zachary, PhD,<sup>4</sup> David J Abraham, PhD,<sup>3</sup> Janice Tsui, MD,<sup>3</sup> and Adrian J Hobbs, PhD<sup>1</sup> 30'**

<sup>1</sup>William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

<sup>2</sup>University of Sydney, Kolling Institute of Medical Research, St Leonards, 2065, Australia

<sup>3</sup>Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Campus, London, NW3 2PF, UK

<sup>4</sup>Centre for Cardiovascular Biology and Medicine, Division of Medicine, The Rayne Building, University College London, London WC1E 6JJ, UK

*Endothelium-derived C-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodelling*

T-KA1-3 **Elizabeth S. Fernandes,<sup>1,2</sup> Liziane C. M. da Silva,<sup>3</sup> Catielen P. Pavi,<sup>3</sup> Beatriz P. Savi,<sup>4</sup> Seigo Nagashima,<sup>5</sup> Samara Damasceno,<sup>5</sup> Ayda H. Schneider,<sup>3</sup> Izabella T. Silva,<sup>3</sup> Gislaine Fongaro,<sup>6</sup> Maria R. Q. Bomfim,<sup>7</sup> Adara Aurea,<sup>8</sup> Sérgio J. Macedo Júnior,<sup>9</sup> João Valente,<sup>5</sup> Thiago M. Cunha,<sup>4</sup> Lucia de Noronha,<sup>7</sup> Joao B. Calixto,<sup>9</sup> Susan D. Brain 30'**

<sup>1</sup>Faculdades Pequeno Príncipe, Curitiba, Brazil

<sup>2</sup> Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil

<sup>3</sup>Universidade Federal de Santa Catarina, Florianópolis, Brazil

<sup>4</sup>Pontifícia Universidade Católica Paraná, Curitiba, Brazil

<sup>5</sup>Universidade de São Paulo, Ribeirão Preto, Brazil

<sup>6</sup>Universidade CEUMA, São Luis, Brazil

<sup>7</sup>Centro de Inovação e Ensaios Pré-clínicos, Florianópolis, Brazil

<sup>8</sup>Universidade Federal do Paraná, Curitiba, Brazil

<sup>9</sup>King's College London, London, UK

*Unveiling the mechanisms of Chikungunya-induced pain*

- 10:30-12:30 T-KB1 Opioid research: past, present and future**  
Chairs: Mahmoud Al-Khrasani, Pál Riba
- T-KB1-1** **1Michael Schaefer, <sup>1</sup>Mohammed Shaqura, <sup>1</sup>Shaaban Mousa 15'**  
<sup>1</sup>Dep. of Anaesthesiology, Campus Benjamin Franklin, Charite University Berlin, Hindenburgdamm 30, 12203 Berlin, Germany  
*Distinct expression and functional profile of Mu-, Delta-, and Kappa-Opioid receptors in human dorsal root ganglia*
- T-KB1-2** **1Carmela Parenti, <sup>2</sup>Simona Denaro, <sup>2</sup>Nunzio Vicario, <sup>2</sup>Rosalba Parenti, <sup>1</sup>Rita Turnaturi, <sup>1,2</sup>Annamaria Fidilio, <sup>1</sup>Margherita Grasso, <sup>1</sup>Lorella Pasquinucci 15'**  
<sup>1</sup>Department of Drug and Health Sciences, University of Catania, Italy  
<sup>2</sup>Department of Biomedical and Biotechnological Sciences, University of Catania, Italy  
*Dual-target ligands and pain: our experience*
- T-KB1-3** **1Shaaban Mousa, <sup>1</sup>Mohammed Shaqura, <sup>1</sup>Michael Schaefer 15'**  
<sup>1</sup>Dep. of Anaesthesiology, Campus Benjamin Franklin, Charite University Berlin, Hindenburgdamm 30, 12203 Berlin, Germany  
*Peripheral analgesic effects of opioids for painful diabetic neuropathy*
- T-KB1-4** **1Sanzio Candeletti, <sup>1</sup>Laura Rullo, <sup>1</sup>Camilla Morosini, <sup>1</sup>Loredana M. Losapio, <sup>1</sup>Antonio Lacorte, <sup>1</sup>Marco Cristani, <sup>1</sup>Patrizia Romualdi 15'**  
<sup>1</sup>Dept. of Pharmacy and Biotechnology, Alma Mater Studiorum – University of Bologna, Bologna, Italy  
*The affective component of chronic pain and the opioid system*
- T-KB1-5** **1Patrizia Romualdi, <sup>1</sup>Laura Rullo, <sup>1</sup>Camilla Morosini, <sup>1</sup>Loredana M. Losapio, <sup>1</sup>Antonio Lacorte, <sup>1</sup>Marco Cristani, <sup>1</sup>Sanzio Candeletti 15'**  
<sup>1</sup>Dept. of Pharmacy and Biotechnology, Alma Mater Studiorum- University of Bologna, Bologna, Italy  
*Opioids in chronic pain treatment and risk of OUD*
- T-KB1-6** **Tibor Soós 15'**  
HUN-REN Research Centre for Natural Sciences, Institute of Organic Chemistry, Budapest  
*Dawn of a novel pain treatment: Synthesis and structural plasticity of the most potent atypical opioid kratom alkaloid*
- T-KB1-7** **1Al-Khrasani Mahmoud, <sup>1</sup>Galambos Anna Rita, <sup>1</sup>Karádi Dávid Á., <sup>1</sup>Nariman Essmat, <sup>1</sup>Sarah K. Abbood, <sup>1</sup>Király Kornél, <sup>2</sup>Lakatos Péter P., <sup>1,4</sup>Zádor Ferenc, <sup>3</sup>Köles László, <sup>2</sup>Tábi Tamás, <sup>1</sup>Riba Pál, <sup>1</sup>Ifj. Hárssing G. László, <sup>1</sup>Fürst Susanna 15'**

<sup>1</sup> Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1445 Budapest, Hungary

<sup>2</sup> Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, Nagyvárad tér 4, Budapest, Hungary

<sup>3</sup> Department of Oral Biology, Semmelweis University, H-1089 Budapest, Hungary

<sup>4</sup> Pharmacological and Drug Safety Research, Gedeon Richter Plc, H-1475 Budapest, Hungary

*Glycine transporter 1 and AT1 receptor inhibitors: novel strategies to decrease morphine analgesic tolerance*

**10:30-12:30 T-KC1 Beyond technicality: analytical science as an attitude**

Chairs: Csaba Szántay, Pál Szabó

**Chairmen's introductory remarks 10'**

**T-KC1-1 Zoltán Béni 20'**

Spectroscopic Research Department, Gedeon Richter Plc.

*NMR at the frontier: structure elucidation of mysterious trace components*

**T-KC1-2 Pál Szabó 10'**

HUN-REN Research Centre for Natural Sciences, Budapest

*The role of high resolution mass spectrometry in the identification of 5-F-cumylpegaclon metabolites*

**T-KC1-3 László Valkai 20'**

In vitro Metabolism Laboratory, Gedeon Richter Plc, Budapest

*Behind the scenes: light absorption-based detection on in vitro ADME test samples*

**T-KC1-4 <sup>1</sup>Tibor Renkecz, <sup>1,2,3</sup>Aliz Széles, <sup>1</sup>Károly Schöll, <sup>1</sup>Ilona Pasics,**

<sup>4</sup>Scopchanova Sirma, <sup>1</sup>Gábor Hirka, <sup>2</sup>Katalin Monostory **20'**

<sup>1</sup>Toxi-Coop Toxicological Research Center, Budapest,

<sup>2</sup>HUN-REN Research Center for Natural Sciences, Budapest,

<sup>3</sup>Semmelweis University, Budapest,

<sup>4</sup>SCC Scientific Consulting Company, Bad Kreuznach

*Different derivatization approaches to enable toxicokinetic analysis of curious analytes*

**Panel discussion 30'**

**12:30-13:30 Lunch - Mátra Restaurant**

**13:30-14:00 T-KA2 KEYNOTE 4 - Sönke Behrends 30'**

<sup>1</sup>Pharmacology, University of Braunschweig, Germany

<sup>2</sup>Semmelweis University Budapest, Asklepios Campus Hamburg, Germany

*Precision pharmacology: targeting enzyme isoforms for tailored therapeutics*

- 13:30-14:00 T-KB2 KEYNOTE 5 - Soraia Costa 30'**
- <sup>1</sup>Jorge L Dallazen, PhD, <sup>1</sup>Larissa G Santos, MSc, <sup>1</sup>Simone A Teixeira, PhD, <sup>2</sup>John Wallace, PhD, <sup>1</sup>Marcelo N Muscará, PhD, <sup>1</sup>**Soraia K P Costa, PhD.**
- <sup>1</sup>Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Av. Prof Lineu Prestes, 1524 São Paulo/SP, 05508-000, Brazil
- <sup>2</sup>Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, T2N 1N4, Canada.
- Exploring opportunities and challenges of hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs for effective pain control and gastric integrity*
- 14:00-15:30 T-KA3 Novel approaches to treat gastrointestinal and pancreatic diseases**
- Chairs: Zoltán Zádori, József Maléth
- T-KA3-1** <sup>1,2,9</sup>**Viktória Venglovecz**, <sup>2,3</sup>Anna Grassalkovich, <sup>2,3,4</sup>Emese Tóth, <sup>1</sup>Attila Ébert, <sup>1</sup>Eleonóra Gál, <sup>1</sup>Marietta Margaréta Korsós, <sup>3,5,6</sup>József Maléth, <sup>7</sup>Zoltán Rakonczay Jr., <sup>8</sup>Zsolt Galla, <sup>8</sup>Péter Monostori, <sup>2,9,10,11</sup>Péter Hegyi **15+3<sup>1</sup>**
- <sup>1</sup>Department of Pharmacology and Pharmacotherapy, University of Szeged, Hungary,
- <sup>2</sup>Translational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, Hungary,
- <sup>3</sup>Department of Medicine, University of Szeged, Hungary,
- <sup>4</sup>Department of Health Sciences, Department of Theoretical and Integrative Health Sciences, University of Debrecen, Hungary,
- <sup>5</sup>HCEMM–SZTE Molecular Gastroenterology Research Group, University of Szeged, Hungary,
- <sup>6</sup>ELKH–USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Hungary,
- <sup>7</sup>Department of Pathophysiology, University of Szeged, Hungary,
- <sup>8</sup>Metabolic and Newborn Screening Laboratory, Department of Paediatrics, University of Szeged, Hungary,
- <sup>9</sup>Institute for Translational Medicine, Medical School, University of Pécs, Hungary,
- <sup>10</sup>Centre for Translational Medicine, Semmelweis University, Hungary,
- <sup>11</sup>Institute for Pancreatic Disorders, Semmelweis University, Hungary  
*Orkambi is a potential therapeutic option for acute pancreatitis*
- T-KA3-2** <sup>1</sup>**Eszter M. Horváth**, <sup>1</sup>Máté Bencsics, <sup>1</sup>Ke Haoran, <sup>1</sup>Bálint Bányai, <sup>1</sup>Roland Csépányi-Kömi, <sup>1</sup>Péter Sasvári, <sup>2</sup>Dantzer Françoise, <sup>2</sup>Hanini Najat, Rita Benkő **15+3<sup>1</sup>**

<sup>1</sup>Department of Physiology, Semmelweis University, Budapest, Hungary, <sup>2</sup>UMR7242, Biotechnology and Cell Signaling, CNRS/Université de Strasbourg, Strasbourg, France

*T-cell specific PARP-2 downregulation in LPS induced inflammation of the large intestine*

**T-KA3-3** **Zoltán S. Zádori**, <sup>1,2</sup>Barbara Hutka, <sup>1</sup>Arezoo Haghghi, <sup>1</sup>András S. Tóth, <sup>1</sup>Szilvia B. László, <sup>1</sup>Zsuzsanna Demeter, <sup>1</sup>Gerda Wachtl, <sup>1</sup>Klára Gyires **15+3'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary,

<sup>2</sup> Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary

*Searching for new targets for treatment of NSAID enteropathy*

**T-KA3-4** **Edyta Korbut**, <sup>1</sup>Główacka Urszula, <sup>1</sup>Krukowska Kinga, <sup>1,2</sup>Wierdak Mateusz, <sup>3</sup>Vignane Thibaut, <sup>1</sup>Magierowska Katarzyna, <sup>1,4</sup>Bakalarz Dominik, <sup>3</sup>Filipovic Milos R, <sup>1</sup>Magierowski Marcin **15+3'**

<sup>1</sup>Department of Physiology, Jagiellonian University Medical College, Cracow, Poland

<sup>2</sup>2nd Department of Surgery, Jagiellonian University Medical College, Cracow, Poland

<sup>3</sup>Leibniz-Institut für Analytische Wissenschaften-ISAS e.V. Dortmund, Germany

<sup>4</sup>Department of Forensic Toxicology, Institute of Forensic Research, Cracow, Poland

*Controllable gaseous mediators delivery, pathway-specific proteins persulfidation and translational insights into Barrett's esophagus pathogenesis*

**T-KA3-5** **József Maléth** **15+3'**

<sup>1</sup>Department of Medicine, University of Szeged, Szeged, Hungary; ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Szeged, Hungary;

<sup>2</sup>HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged, Szeged, Hungary

Novel therapeutic targets in chronic pancreatitis: preclinical findings and translational possibilities

**14:00-15:30 T-KB3 Advances in the pharmacotherapy of pain and inflammation**

Chairs: Valéria Tékus, Zsuzsanna Helyes, Peter Bai

**T-KB3-1** Henrietta Papp<sup>1,2,\*</sup>, Judit Bóvári-Biri<sup>3,\*</sup>, Krisztina Bánfai<sup>3,\*</sup>, Tóth Emese<sup>8,\*</sup>, Péter Juhász<sup>4</sup>, Mohamed Mahdi<sup>5</sup>, Lilian Cristina Russo<sup>6</sup>, Dávid Bajusz<sup>7</sup>, Adrienn Sipos<sup>8,9</sup>, László Petri<sup>7</sup>, Tibor Viktor Szalai<sup>7</sup>, Ágnes Kemény<sup>2,10,11</sup>, Gyula Batta<sup>12</sup>, Orsolya Mónzner<sup>13</sup>, Dorottya Vaskó<sup>14</sup>, Edit Hirsch<sup>14</sup>, Péter Bohus<sup>15</sup>, Gábor Méhes<sup>4</sup>, József Tőzsér<sup>5</sup>, Nicola J. Curtin<sup>16</sup>, Zsuzsanna Helyes<sup>2,10</sup>, Attila Tóth<sup>17</sup>, Nicolas C. Hoch<sup>6</sup>, Ferenc Jakab<sup>1,2</sup>, György M. Keserű<sup>7</sup>, Judit E. Pongrácz<sup>2</sup>, **Péter Bai**<sup>8,9,18,19</sup> **15+5'**

<sup>1</sup>National Laboratory of Virology, University of Pécs, 7624, Pécs, Hungary and Institute of Biology, Faculty of Sciences, University of Pécs, 7624, Pécs, Hungary

<sup>2</sup>Szentagothai Research Centre, University of Pécs, 7624, Pécs, Hungary

<sup>3</sup>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pécs, 7624, Pécs, Hungary

<sup>4</sup>Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary;

<sup>5</sup>Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032, Hungary;

<sup>6</sup>Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil;

<sup>7</sup>Medicinal Chemistry Research Group, Research Centre for Natural Sciences, 1117, Budapest, Hungary

<sup>8</sup>Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary;

<sup>9</sup>MTA-DE Cell Biology and Signaling Research Group ELKH, Debrecen, 4032, Hungary;

<sup>10</sup>Department of Pharmacology and Pharmacotherapy, Medical School; Centre for Neuroscience, 7624, Pécs, Hungary

<sup>11</sup>Department of Medical Biology, Medical School, Pécs, 7624, Hungary

<sup>12</sup>Department of Organic Chemistry, Faculty of Science and Technology, University of Debrecen, 4032, Debrecen, Hungary

<sup>13</sup>Doctoral School of Molecular Medicine, Semmelweis University, 1094, Budapest, Hungary and Institute of Enzymology, Research Centre for Natural Sciences, 1117, Budapest, Hungary

<sup>14</sup>Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, 1111, Budapest, Hungary

<sup>15</sup>Erzsébet Hospital, Sátoraljaújhely, 3980, Hungary

<sup>16</sup>Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, NE2 4HH, Newcastle upon Tyne, UK

<sup>17</sup>Section of Clinical Physiology, Department of Cardiology, University of Debrecen, Debrecen, 4032, Hungary;

*Repurposing PARP inhibitors for treating COVID-19-related inflammation*

**T-KB3-2** <sup>1</sup>Ivica Matak **15+5'**

<sup>1</sup>University of Zagreb School of Medicine, Zagreb

*Antinociceptive action of botulinum toxin A and recombinant botulinum toxin-based molecules*

**T-KB3-3** <sup>1,2,3</sup>Valéria Tékus, <sup>1,3,4</sup>Nikolett Szentes, <sup>1,3,4</sup>Barbara Fülöp, <sup>1</sup>Jennet

Pirkulyeva, <sup>1,3</sup>Éva Borbényi, <sup>5</sup>Ádám Dénes, <sup>6,7</sup>Andreas Goebel, <sup>1,3,4,8</sup>Zsuzsanna Helyes **15+5'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary,

<sup>2</sup>Faculty of Health Sciences, Department of Laboratory Diagnostics, University of Pécs, H-7624, Pécs, Hungary;

<sup>3</sup>Hungarian Research Network, University of Pécs, Pécs, Hungary,

<sup>4</sup>National Laboratory for Drug Research and Development, Budapest, Hungary,

<sup>5</sup>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary,

<sup>6</sup>Pain Research Institute, University of Liverpool, Liverpool, United Kingdom,

<sup>7</sup>Department of Pain Medicine, The Walton Centre National Health Service Foundation Trust, Liverpool, United Kingdom,

<sup>8</sup>PharmlnVivo Ltd., Pécs, Hungary

*Fractalkine (CX3CR1) and Interleukin-1 (IL-1) receptors mediate neuroinflammation and related hypersensitivity in mouse models of chronic primary pain*

**T-KB3-4** <sup>1</sup>Göntér Kitti, <sup>2</sup>László Szabolcs, <sup>2</sup>Wagner Ödön, <sup>1</sup>Pozsgai Gábor,

<sup>1</sup>Pintér Erika, <sup>3</sup>Zsófia Hajna **10+5'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs

<sup>2</sup>Department of Inorganic and Analytical Chemistry, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest

*In vivo investigation of combined capsaicin-diclofenac containing transdermal patch in rat models of acute pain*

**T-KB3-5** <sup>1,3</sup>Patrik Székér, <sup>1</sup>Anna Hajdara, <sup>1</sup>Gábor Rácz, <sup>1</sup>József Murányi, <sup>1</sup>Ágota

Csóti, <sup>1</sup>Nikoletta Ngo Hahn, <sup>1</sup>Márton Megyeri, <sup>1</sup>Tamás Kitka, <sup>1</sup>Attila

Brunyánszki, <sup>2</sup>Ágnes Kemény, <sup>2</sup>Erika Pintér, <sup>2</sup>Zsuzsanna Helyes,

<sup>4</sup>György Panyi, <sup>1</sup>Sándor Farkas, <sup>1</sup>Zalán Péterfi, <sup>1</sup>Péter Hornyák,

<sup>3</sup>Norbert Gyöngyösi **10+5'**

<sup>1</sup>VRG Therapeutics Ltd., Budapest,

<sup>2</sup>PharmlnVivo Ltd., Pécs,

<sup>3</sup>Semmelweis University, Institute of Biochemistry and Molecular Biology Department of Molecular Biology, Budapest,

<sup>4</sup>Pharmion LP., Debrecen

*Developing selective KV1.3 inhibitors for the treatment of chronic inflammatory diseases*

- 14:00-15:30 T-KC3 Heart failure - remodeling - seeking answers to open questions - From bench to bedside**
- Chair: Przemysław Leszek
- T-KC3-1 Przemysław Leszek 5'**
- Heart Failure and Transplantology Department; Mechanical Circulatory Support and Transplant Department, National Institute of Cardiology, Warsaw, Poland
- Clinical need for rhythm optimization*
- T-KC3-2 Michał Mączewski 10'**
- Department of Clinical Physiology, Medical Centre of Postgraduate Education, Kiełpin, Poland
- Experimental studies - what they suggest to clinicians*
- T-KC3-3 1,2,3 Zoltán V. Varga, 1,2,3 Márk E. Jakab, 1,2,3 Al-Haddad R. Ayham, 1,2,3 Zsófia Onódi, 1,4 Péter Ferdinand 7,5'**
- <sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,
- <sup>2</sup>HCEMM-SU Cardiometabolic Immunology Research Group, Budapest,
- <sup>3</sup>MTA-SE Momentum Cardio-oncology and Cardio-immunology Research Group, Budapest,
- <sup>4</sup>Pharmahungary Group, Szeged, Hungary
- Antidiabetic drugs repurposed for heart failure*
- T-KC3-4 1,2,3 Zsófia Onódi, 1,4 Péter Ferdinand, 1,2,3 Zoltán V. Varga 7,5'**
- <sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary,
- <sup>2</sup>HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary,
- <sup>3</sup>MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Semmelweis University, Budapest, Hungary,
- <sup>4</sup>Pharmahungary Group, Szeged, Hungary
- Anti-gout medications repurposed for heart failure*
- T-KC3-5 Przemysław Leszek 5'**
- Heart Failure and Transplantology Department; Mechanical Circulatory Support and Transplant Department, National Institute of Cardiology, Warsaw, Poland
- Iron deficiency - a clinician's perspective*
- T-KC3-6 Aleksandra Paterek 10'**
- Centre of Postgraduate Medical Education, Warsaw, Poland
- What basic research teaches us about iron deficiency?*
- T-KC3-7 Michał Mączewski 7,5'**
- Department of Clinical Physiology, Medical Centre of Postgraduate Education, Kiełpin, Poland
- Epicardial fat - how it affects the myocardium*

**T-KC3-8 Aleksandra Paterek 7,5'**

Centre of Postgraduate Medical Education, Warsaw, Poland

*Intramycocardial fat - a novel proarrhythmic factor*

**T-KC3-9 1,2,3 Tamás Kovács, 1,2,3 Ágnes Paál, 1,2,3 Zsombor Hegedűs, 1,2,3 Lilla Szabó, 1,2,3 Zoltán Varga 7,5'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,

<sup>2</sup>SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest,

<sup>3</sup>HCEMM-SU Cardiometabolic Immunology Research Group, Budapest

*Melanoma subtype-dependent cardiotoxicity to immune checkpoint inhibitor therapy*

**T-KC3-10 1,2 Zsombor I. Hegedűs, 1,2,3 Gergely G. Tamás, 1,2,3 Tamás Kovács, 1,2,3 Zsófia Onódi, 4 Bálint Barta, 4 Sayour Alex Ali, 4 Tamás Radovits,**

<sup>4</sup>Béla Merkely, <sup>1,5</sup>Péter Ferdinandy, <sup>1,2,3</sup>Zoltán V. Varga 7,5'

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,

<sup>2</sup>HCEMM-SU Cardiometabolic Immunology Research Group, Budapest,

<sup>3</sup>MTA-SE Momentum Cardio-oncology and Cardio-immunology Research Group, Budapest,

<sup>4</sup>Heart and Vascular Center, Semmelweis University, Budapest, Hungary,

<sup>5</sup>Pharmahungary Group, Szeged, Hungary

*Expression of key immune checkpoints in end-stage heart failure*

**15:30-15:50**

**Coffee break**

**15:50-17:50 T-KA4 Innovative models in pharmacological research**

Chair: Dóra Zelena

**T-KA4-1 <sup>1</sup>Dávid Czimer, <sup>1</sup>Panna Kaluzsa, <sup>2</sup>Krisztina Fülöp, <sup>2</sup>Viola Pomozi, <sup>2</sup>András Váradi, <sup>1</sup>Máté Varga 15+5'**

<sup>1</sup>Department of Genetics, ELTE Eötvös Loránd University, Budapest,

<sup>2</sup>Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest

*From tank to bed in PXE? Using zebrafish to search for pseudoxanthoma elasticum treatments*

**T-KA4-2 <sup>1</sup>Zoltán Veréb 15+5'**

<sup>1</sup> Regenerative Medicine and Cellular Pharmacology Laboratory, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary;

*3D tissue printing in toxicology research*

**T-K4-3** István Fodor, Réka Svigruba, Éva Molnár, Tibor Kiss, and **Zsolt Pirger**  
**15+5'**

<sup>1</sup>Ecophysiological and Environmental Toxicological Research Group,  
HUN-REN Balaton Limnological Research Institute, Tihany, 8237,  
Hungary

*„Top-down” effects of psychoactive compounds on a defined simpler  
nervous system encoding associative memory*

**T-K4-4** **<sup>1</sup>Judit Hargitai 15+5'**

<sup>1</sup>Charles River Laboratories Hungary Kft, Veszprém, Hungary

*The use of in vitro models in toxicology studies*

**T-K4-5** **<sup>1</sup>Dávid Szép**, <sup>1</sup>Ferenc Budán, <sup>2</sup>Kristóf Csepregi, <sup>1</sup>Kinga Dávid, <sup>1</sup>Bianka  
Pál-Dittrich, <sup>1</sup>Attila Sik **15+5'**

<sup>1</sup>University of Pécs, Medical School, Institute of Physiology, Pécs,

<sup>2</sup>University of Pécs, Faculty of Natural Sciences, Institute of Biology,  
Pécs

*The power of zebrafish: swimming to success to find plant-based  
antiepileptic drug candidates*

**T-K4-6** **<sup>1</sup>Kornélia Szebényi 15+5'**

HUN-REN Research Centre for Natural Sciences, Budapest, Hungary

*Human induced pluripotent stem cell-derived organoids for disease  
modeling*

**15:50-17:50 T-KB4** **Novel findings of the TRP channel research by the Hungarian  
scientists**

Chair: Erika Pintér

**T-KB4-1** **Attila Tóth**, Róbert Pórszász, Ahem Gerard P.

University of Debrecen, Faculty of Medicine, Department of  
Physiology

*The vascular biological role of TRPV1*

**T-KB4-2** **István Nagy**

Imperial College London

*TRPV1: back on the list of targets for analgesia*

**T-KB4-3** **András Garami**

Department of Thermophysiology, Institute for Translational  
Medicine, Medical School, University of Pecs, Pecs, Hungary

*Mechanisms of the thermoregulatory effects of TRPV1 antagonists*

**T-KB4-4** <sup>1</sup>Márk Racskó, <sup>1,2</sup>Árpád Kunka, <sup>1,2</sup>Judit Bohács, <sup>1</sup>Erika Lisztes, <sup>2</sup>Rita  
Marincsák, <sup>1</sup> **Balázs István Tóth**

<sup>1</sup>Department of Physiology, Faculty of Medicine, University of  
Debrecen, Debrecen,

<sup>2</sup>Faculty of Dentistry, University of Debrecen, Debrecen

*Sensory TRP channels in the human dental pulp and their role in  
pulpitis*

**T-KB4-5** <sup>1</sup>Erzsébet Kövesdi, <sup>1</sup>Laura Mundrucz, <sup>7</sup>Angela Kecskes, <sup>1</sup>Attila Gyéresi, <sup>1</sup>Máté Deák, <sup>2</sup>Balázs Gaszner, <sup>4</sup>Cecília Szekeres-Paraczky, <sup>4</sup>Zsófia Maglóczky, <sup>3</sup>Rudi Vennekens, <sup>7</sup>Viktória Kormos, <sup>1</sup>**Miklós Kecskés**  
<sup>1</sup> Institute of Physiology, Medical School, University of Pécs, H-7624, Pécs, Hungary,  
<sup>2</sup> Department of Anatomy, Medical School and Research Group for Mood Disorders, Centre for Neuroscience, Szentágothai Research Centre, University of Pécs, H-7624, Pécs, Hungary;  
<sup>3</sup> Laboratory of Ion Channel Research, Biomedical Sciences Group, Department of Cellular and Molecular Medicine, VIB-KU Leuven Center for Brain & Disease Research, KU Leuven, 3000, Leuven, Belgium,  
<sup>4</sup> Human Brain Research Laboratory, HUN-REN Institute of Experimental Medicine, H-1083 Budapest, Hungary,  
<sup>7</sup> Department of Pharmacology and Pharmacotherapy, Centre for Neuroscience, Medical School, University of Pécs, H-7624, Pécs, Hungary

*TRPM4 in hilar mossy cells, a role in epilepsy*

**T-KB4-6** <sup>1</sup>**Péter Sántha**, <sup>2</sup>Ivett Kozma-Szeredi, <sup>2</sup>Orsolya Oszlács, Anett Somogyi and <sup>1,2</sup>Gábor Jancsó  
<sup>1</sup>University of Szeged, Department of Anatomy, Histology and Embryology, Szeged  
<sup>2</sup>University of Szeged and Department of Physiology

*Different contributions of primary sensory neuron subpopulations to the initiation of nerve injury induced spinal microglia activation*

- 15:50-17:50 T-KC4 Translational medicine leading to pharmacology applications**  
Chair: Zoltán Varga
- T-KC4-1** <sup>1,2</sup>**Eszter Farkas**, <sup>1,2</sup>Réka Tóth, <sup>1,2</sup>Anna Törteli, <sup>3</sup>Noémi Kovács, <sup>4</sup> Ildikó Horváth, <sup>3,4</sup>Domokos Máthé, <sup>1,2</sup>Ákos Menyhárt **15+5'**  
<sup>1</sup>HCEMM-USZ Cerebral Blood Flow and Metabolism Research Group, HCEMM Nonprofit Ltd., Szeged,  
<sup>2</sup>Department of Cell Biology and Molecular Medicine, University of Szeged, Szeged,  
<sup>3</sup>HCEMM-SU In Vivo Imaging Advanced Core Facility, Budapest,  
<sup>4</sup>Department of Biophysics and Radiation Biology, Semmelweis University-Faculty of Medicine, Budapest
- Modulation of Aquaporin-4 Expression by Trifluoperazine Augments Functional Recovery after Experimental Ischemic Stroke*
- T-KC4-2** <sup>1</sup>Kolos Nemes, <sup>1</sup>Alexandra Á. Benő, <sup>1</sup>Gabriella Mihalekné Fűr, <sup>1,2</sup>Éva Magó, <sup>1</sup>Petronella Topolcsányi, <sup>1</sup>**Lőrinc S. Pongor 15+5'**

<sup>1</sup>Cancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary,

<sup>2</sup>Genome Integrity and DNA Repair Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary

*Predicting Drug Response Using Gene Expression Signatures in Cell Line Models*

**T-KC4-3 <sup>1,2</sup>Tibor Pankotai 15+5'**

<sup>1</sup> Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Genome Integrity and DNA Repair Core Group, University of Szeged, Szeged, Hungary,

<sup>2</sup> Department of Pathology, University of Szeged, Szeged, Hungary

*The clinical significance of epigenetic, RNAPII and transcriptional variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker*

**T-KC4-4 <sup>1</sup>Karri Lamsa 15+5'**

<sup>1</sup>Hungarian Centre of Excellence for Molecular Medicine Research Group for Human neuron physiology and therapy, Szeged, Hungary

*How neurons in human brain are different from animal model cells, and why this is important?*

**T-KC4-5 <sup>1,2,3</sup> Gábor M. Mórotz, <sup>1,2,3</sup>Nabil V. Sayour, <sup>1,2,3</sup>Tamás G. Gergely, <sup>1,2,3</sup>Viktória É. Tóth, <sup>1,2,3</sup>Tamás Kovács, <sup>1,2</sup>Barnabás Váradi, <sup>1,4,5</sup>Bence Ágg, <sup>1,4,5</sup>Péter Ferdinandy, <sup>1,2,3</sup>Zoltán V. Varga 10+3'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,

<sup>2</sup>HCEMM-SU Cardiometabolic Immunology Research Group, Budapest,

<sup>3</sup>MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest,

<sup>4</sup>MTA-SE System Pharmacology Research Group, Budapest,

<sup>5</sup>Pharmahungary Group, Szeged

*Adrenal Inflammation in heart failure*

**T-KC4-6 <sup>1,2</sup>Viktor Szegedi, <sup>1</sup>Ádám Tiszlavicz, <sup>1</sup>Szabina Furdan, <sup>1</sup>Abdennour Douida, <sup>1,2</sup> Emoke Bakos, <sup>3</sup>Pal Barzo, <sup>4</sup>Gabor Tamas, <sup>5</sup> Attila Szucs, <sup>1,2</sup>Karri Lamsa 10+3'**

<sup>1</sup>Hungarian Centre of Excellence for Molecular Medicine Research Group for Human Neuron Physiology and Therapy, Szeged, Hungary,

<sup>2</sup>Department of Physiology, Anatomy and Neuroscience, University of Szeged, Hungary,

<sup>3</sup>Department of Neurosurgery, University of Szeged, Hungary,

<sup>4</sup>MTA-SZTE Research Group for Cortical Microcircuits, Department of Physiology, Anatomy and Neuroscience, University of Szeged, Hungary,

<sup>5</sup>Neuronal Cell Biology Research Group, Eötvös Loránd University, Budapest, Hungary

*Aging-associated weakening of the action potential in fast-spiking interneurons in the human neocortex*

17:50-18:20	T-KA5	<b>KEYNOTE 6- Biotech 30'</b>
	T-KA5-1	<b>Ágnes Angyal 10'</b>
		GeneTiCA Ltd.
		<i>The power of multiomics</i>
	T-KA5-2	<b>Josef Uskoba 10'</b>
		BioTech a.s.
		<i>BioTech – A Key Partner in Structural Biology Solutions for a Pharmaceutical Industry</i>
	T-KA5-3	<b>Péter Keresztúri 10'</b>
		BioTech Hungary Ltd.
		<i>Deeper insights into cell models with Agilent Cell Analysis instruments</i>
17:50-18:20	T-KB5	<b>KEYNOTE 7 - Michael Bischoff – PAE GmbH 30'</b>
17:50-19:20		<b>POSTER SESSION- Galya Room on the 1st floor and Foyer on the 1st floor</b>
20:00		<b>Gala Dinner - Mátra Restaurant</b>
22:00		<b>Dance- Music Lounge</b>

# June 7, 2024 Friday

8:00	Registration- Hotel Lobby
9:00-10:00	F-KA <b>PLENARY LECTURE -Wan-Wan-Lin 60'</b> Department of Pharmacology, College of Medicine, National Taiwan University <i>Oxidative stress and cell death: Roles of PARP1 and AMPK</i>
10:00-10:30	Coffee break
10:30-12:30	F-KA1 <b>Novel innovative potentials of cyclodextrins in drug formulation and targeted pharmacotherapy</b> <u>Chairs:</u> Éva Szőke, Éva Fenyvesi F-KA1-1 <b><sup>1</sup>Lajos Szente, <sup>1</sup>Éva Fenyvesi 20+5'</b> <sup>1</sup> CycloLab Ltd <i>Antiviral therapies: Cyclodextrins in dual function</i> F-KA1-2 <b><sup>1</sup>Rita Ambrus, <sup>1</sup>Anett Motzwickler-Németh, <sup>1</sup>Patrícia Varga, <sup>1</sup>Csilla Balla-Bartos, <sup>1</sup>Ildikó Csóka 20+5'</b> <sup>1</sup> University of Szeged, Institute of Pharmaceutical Technology and Regulatory Affairs, Szeged <i>Application of cyclodextrin in traditional and alternative drug formulation; case studies</i> F-KA1-3 <b><sup>1</sup>Ágnes Rusznyák, <sup>1</sup>Csenge Urgyán, <sup>1</sup>Katalin Réti-Nagy, <sup>2</sup>István Hajdu, <sup>2</sup>György Trencsényi, <sup>1</sup>Ferenc Fenyvesi 20+5'</b> <sup>1</sup> Department of Molecular and Nanopharmaceutics, University of Debrecen, Debrecen, <sup>2</sup> Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, University of Debrecen, Debrecen <i>Targeting cancer cells by cyclodextrins via endocytosis</i> F-KA1-4 <b><sup>1</sup>Levente Szőcs, <sup>1</sup>Éva Fenyvesi 20+5'</b> <sup>1</sup> CycloLab Cyclodextrin Research & Development Laboratory, Ltd. Budapest <i>Methylated cyclodextrins: understanding quality – bioactivity relationships</i> F-KA1-5 <b><sup>1,2,3</sup>Andrea Nehr-Majoros, <sup>1,2,3</sup>Maja Payrits, <sup>1,2,3</sup>Noémi Bencze, <sup>1,4</sup>Ágnes Kemény, <sup>1,2,3,5</sup>Zsuzsanna Helyes, <sup>1,2,3,5</sup>Éva Szőke 15+5'</b> <sup>1</sup> Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, <sup>2</sup> National Laboratory for Drug Research and Development, Budapest, <sup>3</sup> Centre for Neuroscience, University of Pécs, Pécs, <sup>4</sup> Department of Medical Biology, Faculty of Medicine, University of Pécs, Pécs, <sup>5</sup> HUN-REN PTE Chronic Pain Research Group, Pécs <i>Analgesia via lipid raft disruption by cyclodextrins</i>

- 10:30-12:30 F-KB1** **Searching for new therapies for neurodegenerative diseases**
- Chairs: Erika Pintér and Anikó Borbás
- F-KB1-1** **Sabina Podlewska**, Bugno Ryszard, Satała Grzegorz, Bojarski Andrzej J., Przewłocki Ryszard **15+5'**  
Maj Institute of Pharmacology Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland  
*Machine learning methods in the serve of new drugs development - case study of biased agonists of mu opioid receptor*
- F-KB1-2** **Jadwiga Handzlik 20+5'**  
Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University, Medical College, Krakow, Poland  
*Chalcogen-containing 1,3,5-triazine compounds in search of breakthrough therapy for neurodegenerative diseases*
- F-KB1-3** **Erika Pintér**, <sup>1</sup>Viktória Kormos, <sup>1</sup>Petra Prókay, <sup>1</sup>János Konkoly, <sup>1</sup>Maja Payrits, <sup>1</sup>Éva Borbély, <sup>2</sup>Balázs Gaszner, <sup>3</sup>Dóra Zelena **20+5'**  
<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Hungary,  
<sup>2</sup>Department of Anatomy, Medical School, University of Pécs, Hungary,  
<sup>3</sup>Department of Physiology, Medical School, University of Pécs, Hungary  
*Could the TRPA1 be a promising target in the treatment of CNS diseases?*
- F-KB1-4** **Dániel Priksz**, <sup>2</sup>Balázs Harangi, <sup>3</sup>Mária Lódi, <sup>4</sup>Zoltán Ujhelyi, <sup>5</sup>Dóra Ujvárosy, <sup>1</sup>Rita Erdélyi, <sup>1</sup>Brigitta Bernát, <sup>1</sup>Mariann Bombicz, <sup>1</sup>Vera Tarjányi, <sup>1</sup>Zoltán Szilvássy, <sup>1</sup>Béla Juhász **15+5'**  
<sup>1</sup>Department of Pharmacology and Pharmacotherapy, University of Debrecen, Debrecen, Hungary, <sup>2</sup>Department of Data Science and Visualization, University of Debrecen, Debrecen, Hungary,  
<sup>3</sup>Department of Neuroanatomy and Molecular Brain Research, Ruhr University Bochum, Medical Faculty, Bochum, Germany,  
<sup>4</sup>Department of Pharmaceutical Technology, University of Debrecen, Debrecen, Hungary, <sup>5</sup>Department of Emergency Medicine, University of Debrecen Clinical Centre, Debrecen, Hungary  
*Assessment of the Effects of a Hydroxamic Acid Derivative Drug Candidate on Cognitive Function of Aged Rats*
- F-KB1-5** <sup>1,2</sup>Anna Anoir Abbas, <sup>2</sup>Jimoh Idris J., <sup>3</sup>Anikó Göblös, <sup>4</sup>Barker A. Roger, <sup>3</sup>Zoltán L. Veréb, <sup>5</sup>Johan Jakobsson, <sup>1,3</sup>Lajos Kemény, <sup>2</sup>Mária Judit Molnár, <sup>1,2,5</sup>Karolina Pircs **10+5'**  
<sup>1</sup> HCEMM, Szeged, <sup>2</sup> Semmelweis University, Budapest, <sup>3</sup> University of Szeged, Szeged, <sup>4</sup> University of Cambridge, Cambridge, <sup>5</sup> Lund University, Lund  
*Studying the effect of cariprazine in induced neurons directly reprogrammed from Huntington's disease patient's fibroblasts*

**F-KB1-6** <sup>1</sup>**Kinga Vörös**, <sup>2</sup>Dimitris Apostolopoulos, <sup>1</sup>Anna A. Abbas, <sup>1</sup>Danics Les,  
<sup>2</sup>Fazal Shaline, <sup>2</sup>Barker A. Roger, <sup>1,3</sup>Karolina Pircs **10+5'**  
<sup>1</sup>HCEMM-Semmelweis University, Budapest, Hungary, <sup>2</sup>University of Cambridge, Cambridge, UK, <sup>3</sup>Lund University, Lund, Sweden.  
*Felodipine efficiency analysis on induced neurons derived from Huntington's disease FELL-HD clinical trial patients*

**10:30-12:30 F-KC1 Pharmaceutical Medicine Session**

- F-KC1-1** Anna Katalin Baráné Gilicze<sup>1</sup>, **Viola Bardóczy<sup>1</sup>**  
National Center for Public Health and Pharmacy Department of Centralised Procedures and Biologicals  
*Quality requirements for biologicals in clinical trials*
- F-KC1-2** <sup>1</sup>**Sandor Kerpel-Fronius**, <sup>2</sup>Alexander L Becker  
<sup>1</sup>Semmelweis University Department of Pharmacology and Pharmacotherapy  
<sup>2</sup>Consultants in Pharmaceutical Medicine, Dover Heights, Australia  
*The value and importance of a professional ethical code for medicines development*
- F-KC1-3** **Krisztina Szabone Nemesy**  
National Center for Public Health and Pharmacy  
*Clinical trials in Hungary from the perspective of the competent authority*
- F-KC1-4** **Lilla Szabó**  
AstraZeneca Kft., Budapest  
*The role of medical affairs in pharma - focus on real world evidence generation*
- F-KC1-5** **Kata Mazalin**

**12:30-13:30 LUNCH - Mátra Restaurant**

**13:30-14:00 F-KA2 KEYNOTE 8- Gábor Zacher 30'**

- 14:00-15:30 F-KA3 New concepts in cardiovascular pharmacology**  
Chair: István Baczkó
- F-KA3-1** <sup>1</sup>Attila Kiss **20'**  
<sup>1</sup>Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria  
*Cardiovascular benefits of SGLT2i*
- F-KA3-2** <sup>1,2</sup>**Péter Bencsik**, <sup>1,2</sup>Tamara Szabados, <sup>2,3</sup>András Makkos, <sup>2,3</sup>Bettina Benczik, <sup>2,3</sup>Barnabás Váradi, <sup>2,3</sup>Bence Ágg, <sup>3</sup>Zoltán V. Varga, <sup>1,2,3</sup>Anikó Görbe, <sup>2,3</sup>Péter Ferdinand **20'**

<sup>1</sup>Cardiovascular Research Group, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Dóm tér 12, H-6720, Szeged, Hungary,

<sup>2</sup>Pharmahungary Group, Hajnóczy 6, H-6722, Szeged, Hungary,

<sup>3</sup>Cardiometabolic and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4, 1089, Budapest, Hungary  
*Cardioprotection by exogenous microRNA-125b\* mimic in a mouse model of acute myocardial infarction*

**F-KA3-3** <sup>1</sup>Tibor Hornyik, <sup>2</sup>Ilona Bodi, <sup>2</sup>Lea Mettke, <sup>2</sup>Konstantin Michaelides, <sup>4</sup>Stefan Meier, <sup>3</sup>Saranda Nimani, <sup>2</sup>Stefanie Perez-Feliz, <sup>5</sup>Ibrahim el-Battrawy, <sup>6</sup>Heiko Bugger, <sup>2</sup>Manfred Zehender, <sup>7</sup>Michael Brunner, <sup>4,8</sup>Jordi Heijman, <sup>2,3</sup>Katja E. Odening **20'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, University of Szeged Albert Szent-Györgyi Medical School,

<sup>2</sup>Institute of Experimental Cardiovascular Medicine, Heart Center University of Freiburg, Medical Faculty, Freiburg, Germany;

<sup>3</sup>Translational Cardiology, Department of Cardiology, Inselspital, Bern University Hospital, and Department of Physiology, University of Bern, Bern, Switzerland,

<sup>4</sup> Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University and Maastricht University Medical Center, Maastricht, NL,

<sup>5</sup>First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim, University of Heidelberg;

<sup>6</sup>Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria;

<sup>7</sup>Department of Cardiology and Medical Intensive Care, St. Josefkrankenhaus, Freiburg, Germany.

<sup>8</sup>Gottfried Schatz Research Center, Division of Medical Physics and Biophysics, Medical University of Graz, Graz, Austria

*Beneficial APD/QT normalizing effects of L-Carnitine in transgenic SQT1 rabbit model*

**F-KA3-4** <sup>1</sup>Anikó Görbe, <sup>1,2</sup>Zoltán Giricz, <sup>1,2</sup>Péter Ferdinand **20'**

<sup>1</sup>Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary,

<sup>2</sup>Pharmahungary Group, Szeged, Hungary

*Hidden cardiotoxicity and cardioprotection: development of preclinical test platforms from in vitro to in vivo models*

**14:00-15:30 F-KB3 Pharmacological aspects of the neurovascular unit**

Chairs: Mária Deli, István Krizbai

**F-KB3-1** Ádám Dénes **20'**

HUN-REN Institute of Experimental Medicine

*Role of microglia in modulation of cerebral circulation and neurovascular coupling*

- F-KB3-2** **Imola Wilhelm**, Kinga Molnár, Ádám Mészáros, Csilla Fazakas, István Krizbai **20'**  
HUN-REN Biological Research Centre, Szeged  
*Targeting the brain metastatic environment*
- F-KB3-3** **Szilvia Veszelka**, <sup>1</sup>Mária Mészáros, <sup>1,2</sup>Anikó Szecskó, <sup>1,2</sup>Gergő Porkoláb, <sup>1</sup>Koppány Párdi, <sup>1</sup>Janet Adegbite, <sup>1</sup> Mária Deli **20'**  
<sup>1</sup>HUN-REN Biological Research Centre, Szeged,  
<sup>2</sup>Doctoral School of Biology, University of Szeged, Szeged  
*Protection of brain endothelial cells as a therapeutic target in central nervous system diseases*
- F-KB3-4** **Mária Mészáros**, <sup>2</sup>Thi Ha My Phan, <sup>1,3</sup>Judit P. Vigh, <sup>1,3</sup>Gergő Porkoláb, <sup>1</sup>Anna Kocsis, <sup>1</sup> Emese K. Páli, <sup>1,4</sup>Tamás F. Polgár, <sup>1</sup>Fruzsina R. Walter, <sup>2</sup>Jeng-Shiung Jan, <sup>5</sup>Tamás Janáky, <sup>1</sup>Szilvia Veszelka and <sup>1</sup>Mária A. Deli **15'**  
<sup>1</sup>Institute of Biophysics, HUN-REN Biological Research Centre, Temesvári krt. 62, H-6726 Szeged, Hungary;  
<sup>2</sup>Department of Chemical Engineering, National Cheng Kung University, Tainan 70101, Taiwan;  
<sup>3</sup>Doctoral School of Biology, University of Szeged, Dugonics tér 13, H-6720 Szeged, Hungary;  
<sup>4</sup>Theoretical Medicine Doctoral School, University of Szeged, Tisza Lajos krt. 97, H-6722 Szeged, Hungary;  
<sup>5</sup>Department of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary  
*Alanine and glutathione targeting of dopamine- or ibuprofen-coupled polypeptide nanocarriers elevates crossing across the blood-brain barrier and protective effects*
- F-KB3-5** <sup>1,2</sup>Szilvia Kecskés, <sup>1,2</sup>Akos Menyhart, <sup>1,2</sup>Eszter Farkas **15'**  
<sup>1</sup>HCEMM-USZ Cerebral Blood Flow and Metabolism Research Group, HCEMM Nonprofit Ltd., Szeged, Hungary,  
<sup>2</sup>Department of Cell Biology and Molecular Medicine, University of Szeged, Szeged, Hungary  
*Dasatinib and Quercetin are protective in focal cerebral ischemia in aged rats*

- 14:00-15:30 F-KC3** **The power of systematic reviews and meta-analyses in the translation of available clinical evidence and to initiate further research**  
Chair: Gábor Varga
- F-KC3-1** **Péter Hegyi** **40'**  
<sup>1</sup>Centre for Translational Medicine, Semmelweis University, Budapest,  
<sup>2</sup>Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary,

<sup>3</sup>Institute for Translational Medicine, Medical School, University of Pécs, Pecs, Hungary

*Translational Medicine – From bedside to bench and to bedside again*

**F-KC3-2 1,<sup>2</sup>Dezső Csupor 25'**

<sup>1</sup>Institute of Clinical Pharmacy, University of Szeged, Szeged,

<sup>2</sup>Institute for Translational Medicine, University of Pécs, Pécs

*TRANSLATIONAL MEDICINE – Clinical investigations of natural products initiated by meta-analyses*

**F-KC3-3 1,<sup>2</sup>Gábor Varga 25'**

<sup>1</sup>Centre for Translational Medicine, Semmelweis University, Budapest,

<sup>2</sup>Department of Oral Biology, Semmelweis University, Budapest

*Translational Medicine – From molecular physiology to meta-analyses to molecular pharmacology of epithelial ion transport and transport products*

**15:30-15:50**

**Coffee break**

**15:50-17:20 F-KA4 Cell and gene therapy – the way to clinical application**

Chairs: András Dinnyés, Péter Ferdinandy

**F-KA4-1 András Dinnyés<sup>1,2,3</sup>, Anita Fehér<sup>1</sup>, Suchitra Muenthaisong<sup>1</sup>, Laura Colar Zanjko<sup>1,3</sup>, Andrea Balogh<sup>1</sup>, Kornél Kistamás<sup>1</sup>, Krisztina Bánfai<sup>1</sup> 15+3'**

<sup>1</sup>BioTalentum Ltd., Gödöllő, <sup>2</sup>Department of Cell Biology and Molecular Medicine, USZ, <sup>3</sup>Department of Physiology and Animal Health, Institute of Physiology and Animal Nutrition, MATE, Gödöllő  
*Progress report on developments towards human cell and gene therapy and xenoorgan transplantation*

**F-KA4-2 László Csernák, Kajdácsi Erika, Bihari György, Vadicsku Dorina, Kocsis Boglárka, Debreczeni Márta Lídia, Demeter Flóra 15+3'**  
Cell Biology and Cell Therapy Group, Department of Internal Medicine and Haematology, Semmelweis University, Budapest  
*A multipurpose anti-inflammatory therapeutic agent: mesenchymal stem cells*

**F-KA4-3 1,<sup>2</sup>Bence Ágg, <sup>1,2</sup>Benczik Bettina, <sup>1</sup>Balogh Olivér, <sup>1</sup>Váczy-Földi Máté, <sup>1</sup>Bereczki Zoltán, <sup>1</sup>Pétervári Mátyás, <sup>1,2</sup>Ferdinandy Péter 15+3'**  
<sup>1</sup>Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,  
<sup>2</sup>Pharmahungary Group, Szeged  
*Network theoretical and machine-learning-based analysis of the interactome for the development of oligonucleotide therapies in cardiovascular diseases*

**F-KA4-4 Zoltán Veréb<sup>1,2</sup>, Diána Szűcs<sup>1,2</sup>, Tamás Monostori<sup>1,2</sup>, Lajos Kemény<sup>1,2,3</sup> 15+3'**

<sup>1</sup> Regenerative Medicine and Cellular Pharmacology Laboratory, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary;

<sup>2</sup> Centre of Excellence for Interdisciplinary Research, Development and Innovation, University of Szeged, Szeged, Hungary

<sup>3</sup> Hungarian Centre of Excellence for Molecular Medicine-USz Skin Research Group, University of Szeged, Szeged, Hungary.

*Pre-clinical development of a cell therapy product*

**F-KA4-5 Péter Ferdinandy 15+3'**

MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; and Pharmahungary Group, Szeged, Hungary

*Development of small non-coding RNA therapeutics: the example of protectomiR miR-450a mimic*

**15:50-17:20 F-KB4 Research relationships between industry and academia**

Chair: Viktor Román

**F-KB4-1 <sup>1,2</sup>Balázs Lendvai 20'**

<sup>1</sup>Gedeon Richter Plc, Pharmacological and Drug Safety Department, Budapest

<sup>2</sup>Department of Richter, Semmelweis University, Budapest

*Ecosystem network around Gedeon Richter Plc.*

**F-KB4-2 Zsolt Némethy 20'**

Gedeon Richter Plc., Laboratory of Systems Biology, Budapest

*Optimization of novel α7 nicotinic acetylcholine receptor positive allosteric modulators and the discovery of a preclinical development candidate molecule*

**F-KB4-3 Szilvia Benkő 20'**

Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen

*Intracellular pattern recognition nod-like receptors (NLRs) in different macrophage subpopulations*

**F-KB4-4 <sup>1,2,3</sup>István Hernádi, <sup>1,2</sup>Anna Padányi, <sup>1</sup>Evelin Kiefer, <sup>1</sup>Antonietta Vitális-Kovács, <sup>1</sup>Rafaella M. Riszt, <sup>1</sup>Balázs Knakker 20'**

<sup>1</sup>Grastyán Translational Research Centre, University of Pécs – Gedeon Richter Plc., Hungary,

<sup>2</sup>Medical School, University of Pécs, Hungary,

<sup>3</sup>Institute of Biology, Faculty of Sciences, University of Pécs, Hungary

*Development of a complex translational test battery for the investigation of cortical excitability in non-human primates*

**17:20-17:40 F-KA5 Awards Ceremony- Young Investigators- Oral and Poster Closing of the Conference**